CJC-1295 vs Sermorelin: A Complete Research Comparison

These materials are research-grade reference compounds sold for laboratory research use only. They are not for human or veterinary use.

CJC-1295 and sermorelin are both analogs of growth-hormone-releasing hormone (GHRH). Unlike many peptide comparisons this one is between two members of the same class acting at the same receptor. What separates them is engineering: sermorelin is the minimal active fragment of GHRH, while CJC-1295 is a modified analog designed for greater stability. That makes the pair a useful case study in how structural modification changes a peptide’s research profile without changing its target.

This article compares them in depth and strictly in research terms: their identity and modifications, the shared GHRH-receptor mechanism, what the literature reports, and how each is verified and handled. Every finding is framed within its experimental context, and nothing here is guidance for human or veterinary use.

At a Glance

• Both are GHRH analogs studied at the GHRH receptor.
• Sermorelin corresponds to the GHRH(1-29) fragment, the minimal active sequence.
• CJC-1295 is a modified GHRH(1-29) analog; a drug-affinity-complex (DAC) version is described as extending circulating half-life in research settings.
• The comparison is about structural engineering and stability, not receptor target.
• Both are research chemicals for laboratory use only, verified per lot by HPLC and mass spectrometry.

Quick Comparison

Attribute	CJC-1295	Sermorelin
Peptide class	GHRH analog	GHRH analog
Receptor studied	GHRH receptor	GHRH receptor
Basis	Modified GHRH(1-29) analog	GHRH(1-29) fragment
Key design feature	Stabilizing modifications; DAC version studied for extended half-life	Minimal active fragment, no stabilizing complex
Comparison axis	Engineered stability	Baseline active sequence
Verification	HPLC + mass spectrometry, per-lot COA	HPLC + mass spectrometry, per-lot COA

What Sermorelin Is?

Sermorelin is the amidated N-terminal 29-residue fragment of growth-hormone-releasing hormone. GHRH’s activity resides largely in its N-terminal region, and the 1-29 fragment is the shortest sequence that retains that activity, which is why sermorelin is studied as a compact stand-in for the natural releasing hormone. It carries no stabilizing complex, so in research it represents the baseline behavior of the active GHRH sequence. Exact molecular weight and purity for any lot are documented on the Certificate of Analysis.

What CJC-1295 Is?

CJC-1295 is a modified analog built on the same GHRH(1-29) backbone but carrying substitutions intended to increase stability. A distinct version incorporating a drug-affinity complex (DAC) is described in the literature as binding to serum albumin, which is associated with a substantially extended circulating half-life in research settings (Teichman et al., 2006). The non-DAC modified analog and the DAC version are studied for how these modifications change exposure relative to the baseline fragment. Exact molecular weight and purity for any lot are documented on the Certificate of Analysis.

Same Receptor, Different Engineering

Because both peptides act at the GHRH receptor, the comparison is not about which pathway is engaged but about how modifications affect the molecule’s behavior. Sermorelin provides the baseline; CJC-1295 shows what stabilizing changes do. This makes the two a natural pairing for studying structure-stability relationships within a single receptor system.

What the Research Literature Reports?

The GHRH-analog literature describes sermorelin as the active N-terminal fragment and CJC-1295 as a stabilized analog, with the DAC modification studied for prolonged exposure via albumin binding (Teichman et al., 2006). The GHRP and secretagogue literature provides broader context for how the growth-hormone axis is studied, including the relationship between GHRH analogs and the separate ghrelin-receptor arm (Bowers, 2012). These are pharmacological and research observations, not statements about human outcomes.

Structure, Stability, and Research Handling

The central research variable here is stability. Sermorelin, as an unmodified fragment, is studied as the shorter-lived baseline; CJC-1295, through its modifications and, in the DAC version, albumin binding, is studied for extended exposure. General peptide-stability principles, including susceptibility to enzymatic cleavage, underlie why such modifications are made. Lot-specific stability is documented on the Certificate of Analysis rather than as a blanket duration.

How Researchers Choose Between Them?

Since they share a receptor, the choice usually comes down to the stability profile a study needs and the specific modification being investigated. A study of the baseline active GHRH sequence points to sermorelin; a study of engineered stability or extended exposure points to CJC-1295, with the DAC version relevant when prolonged exposure is the variable of interest. The available literature for the specific model is a further factor.

Chemical Identity and Verification

Both are verified by mass spectrometry for identity and HPLC for purity, with results on a lot-specific Certificate of Analysis. Net peptide content is distinct from chromatographic purity. Reconcile every molecular figure against the COA before use.

Storage and Handling in a Laboratory Context

Store sealed material cold, shield it from light, and avoid repeated freeze-thaw. Lyophilized material is generally more stable than material in solution. Lot-specific stability is documented on the COA.

Research Limitations and Open Questions

Both peptides are studied largely in research and model systems, and findings do not translate directly to any human context. The distinction between the modified analog and the DAC version is important and is sometimes blurred in secondary sources, so researchers should confirm exactly which form a study or product refers to.

Frequently Asked Questions

What is the difference between CJC-1295 and sermorelin?

Both are GHRH analogs acting at the same receptor. Sermorelin is the unmodified GHRH(1-29) fragment; CJC-1295 is a modified analog studied for greater stability, with a DAC version studied for extended half-life.

What does the DAC modification do in research?

The drug-affinity-complex version is described as binding serum albumin, which is associated with a substantially extended circulating half-life in research settings (Teichman et al., 2006).

Do they act on the same receptor?

Yes, both engage the GHRH receptor. The differences are structural, not in target.

Is CJC-1295 the same as modified GRF(1-29)?

The non-DAC CJC-1295 is a modified GHRH(1-29) analog; the DAC version adds the albumin-binding complex. Confirm which form a given product or study refers to.

Why compare a fragment with a modified analog?

Because it isolates the effect of stabilizing modifications within a single receptor system, which is informative for structure-stability research.

How is each verified for identity and purity?

By mass spectrometry for identity and HPLC for purity, documented on a lot-specific Certificate of Analysis.

Do these findings apply to people?

No. All cited work is in research or model systems and describes mechanism and research outcomes only.

Related Reading

• CJC-1295 reference page
• Growth-Hormone Secretagogue Research Peptides (class overview)
• Lab Reports

References

1. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone. J Clin Endocrinol Metab. 2006. PMID 16352683.
2. Bowers CY. History to the discovery of ghrelin. Methods Enzymol. 2012. PMID 22975043.

Research-use notice: CJC-1295 and sermorelin are research chemicals sold for laboratory research use only. They are not for human or veterinary use. Every finding is reported in the specific research context of the cited study.